Synthego specializes in biotechnology, focusing on genetic engineering by providing synthetic RNA and gene editing tools. Their products enable scientists to modify genes, which can lead to advancements in disease treatment and agricultural improvements. Synthego serves a variety of clients, including research institutions, pharmaceutical companies, and biotech startups, who utilize their products for drug discovery, disease modeling, and genetic research. The company operates in a growing market driven by increased investment in genetic research and the application of gene editing. Synthego's business model is based on the production and sale of synthetic RNA and gene editing tools, generating revenue through direct sales to clients. Additionally, they offer a platform that grants users access to advanced gene editing capabilities. Synthego aims to be a leading provider of essential tools and services in the genetic engineering field.

Founders Fund

Menlo Ventures

WI Harper Group

OS Fund

SciFi VC

Alexandria Venture Investments

ZhenFund

Jerry Yang

Arab Angel Fund

Intel Capital

RA Capital Management

Wellington Management

Laurion Capital Management

Logos Capital

Perceptive Advisors

Chimera

Moore Strategic Ventures

SoftBank

Gigafund

Declaration Partners

Biotechnology

Synthego

REDWOOD CITY, Calif., Jan. 13, 2025 /PRNewswire/ -- Synthego, a leading supplier of CRISPR solutions, has entered a strategic licensing agreement with global biopharmaceutical company AstraZeneca. This agreement grants Synthego a global license to manufacture and distribute AstraZeneca's novel CRISPR gene editing enzyme, eSpOT-ON, recently published as engineered ePsCas9 , to the worldwide research community. This state-of-the-art nuclease, developed by AstraZeneca, will be paired with Synthego's best-in-class gRNA to enable improved health outcomes.Under the terms of the agreement, Synthego also receives exclusive commercialization rights including the right to sublicense this nuclease for therapeutic and commercial use."Our agreement with AstraZeneca is a testament to our commitment to guiding researchers with customized CRISPR solutions that empower their therapeutic pursuits," said Craig Christianson, CEO of Synthego. "By enhancing our CRISPR expertise with AstraZeneca's novel nuclease, we are poised to expedite the development of transformative therapies, paving a streamlined and accelerated path to clinical advancement."Synthego's innovative approach simplifies the licensing process for CRISPR cell and gene therapies, ensuring that novel and groundbreaking nucleases and gRNAs are within reach for researchers. The company's extensive regulatory and technical expertise further bolsters the therapeutic development pipeline, providing a seamless integration from concept to clinic."We are excited to offer significantly lower upfront fees for rights to a leading CRISPR enzyme enabling therapeutic developers to de-risk their fundraising process, and making overall development costs significantly less than with traditional nucleases," continued Christianson.This licensing agreement marks a significant milestone in the field of CRISPR therapeutics, combining the strengths of Synthego's advanced solutions with AstraZeneca's innovative gene therapy technology

Synthego Signs Strategic Agreement With Astrazeneca To License Crispr Gene Editing Enzyme

SHANGHAI and REDWOOD CITY, Calif. , May 29, 2024 /PRNewswire/ -- HuidaGene Therapeutics ("HuidaGene"), a global clinical-stage biotechnology company focused on advancing CRISPR-based genomic medicines, and Synthego Corporation ("Synthego"), a leading provider of innovative CRISPR solutions for developing cell and gene therapies, proudly announce a partnered licensing agreement for the high-fidelity Cas12 CRISPR nuclease (hfCas12Max). This partnership underscores the significant clinical utility of hfCas12Max, naturally complementing Synthego's focus on advanced GMP manufacturing capabilities. Under this licensing agreement and pursuant to undisclosed financial terms between HuidaGene and Synthego, HuidaGene grants Synthego manufacturing and commercialization rights for the hfCas12Max nuclease and optimized gRNA for research; HuidaGene also grants Synthego the right to sublicense the nuclease for therapeutic use.This partnership will streamline the development of CRISPR-based therapeutic applications, providing developers with access to highly precise, efficient, and next-generation genome editing tools. Xuan Yao, Ph.D., Co-founder and President of HuidaGene, emphasized the significance of this agreement, stating, "HuidaGene's expansive CRISPR intellectual property portfolio distinguishes it as a vanguard in genomic medicine, with a versatile pipeline targeting critical neurological and ophthalmological conditions. Together with Synthego, we are poised to significantly accelerate the advancement of CRISPR-based therapies and deliver life-altering genomic medicines to patients worldwide."Craig Christianson, CEO of Synthego, expressed enthusiasm about the partnership with HuidaGene on hfCas12Max, stating, "The combination of our advanced CRISPR GMP production capabilities and regulatory expertise with HuidaGene's next-generation nuclease technology is a crucial step toward advancing transformative cell and gene therapies

Huidagene And Synthego Announce Licensing Agreement On Next-Generation Gene Editing Enzyme, Hfcas12Max

Synthego also announced the addition of Dr. Bill Skarnes, a pioneer in stem cell research, to the company's advisory board.

Synthego Launches High Throughput Induced Pluripotent Stem Cell Genome Engineering

Leadership change simultaneous to the Eclipse Cell Engineering platform spinout as EditCo BioREDWOOD CITY, Calif., March 27, 2024 /PRNewswire/ -- Synthego Corporation, a leading provider of genome engineering solutions, announced that Paul Dabrowski will step down as Chief Executive Officer, effective immediately. Craig Christianson has been appointed Chief Executive Officer following an extensive search process. Mr. Dabrowski, a co-founder of the company, will continue his role as a Board Director and advisor. Additionally, the company announces the divestiture of the Eclipse Cell Engineering platform as EditCo Bio, Inc., enabling Synthego's unique focus on therapeutic applications of CRISPR."Founding and growing Synthego the past 12 years has been the privilege of a lifetime," said Dabrowski. "Our team has transformed the CRISPR landscape by staying true to our values and providing everyone, from individual scientists to the world's leading biotechnology companies, with unprecedented access to advanced genome engineering

Synthego Announces Ceo Transition To Focus On Enabling Crispr Therapeutics

REDWOOD CITY, Calif., Oct. 4, 2023 /PRNewswire/ -- Synthego, a leading provider of genome engineering solutions, today announced the launch of its IND-enabling (INDe) gRNAs , a transformative product offering that revolutionizes the CRISPR-based cell and gene therapy preclinical pipeline. This innovative offering empowers researchers with high quality gRNAs designed specifically for GLP-regulated preclinical and IND-enabling studies, incorporating comprehensive IND-compliant materials and documentation in their design and production and facilitating a seamless transition from preclinical to clinical applications."IND-enabling gRNA is the culmination of years of learning at Synthego to understand how CRISPR is used in preclinical and clinical applications in order to provide end-to-end support for cell and gene therapy developers," said Paul Dabrowski, CEO of Synthego."INDe gRNAs enhances Synthego's industry-leading coverage of the entire discovery-to-clinic continuum" Tweet thisOn the journey through the regulated landscape of CRISPR-based therapeutic development, every step counts towards realizing groundbreaking ideas for life-changing therapies. The IND-enabling phase plays a pivotal role, involving rigorous safety, toxicity, and efficacy testing of the therapeutic candidate, along with initial interactions with health regulators. This phase culminates in the submission of the Investigational New Drug (IND) application, paving the way for clinical trials.The introduction of INDe gRNAs enhances Synthego's industry-leading coverage of the entire discovery-to-clinic continuum when combined with Synthego's recently inaugurated cutting-edge GMP facility, bolstering its support for the rapidly expanding CRISPR clinical industry. This expansion ensures customer success throughout the entire therapeutic development process

Synthego Bridges Critical Preclinical Gap To Accelerate Crispr-Based Cell And Gene Therapies

Genome engineering company Synthego has partnered with synthetic biology company bit.bio to build a platform that will implement synthetic circuitry in cells for therapeutic applications.

Synthego and bit.bio join forces on genetic engineering platform for cell therapy

Synthego to develop multiplexed and complex genetic engineering strategies, increasing the safety and speed at which bit.bio can engineer human cells for cell therapies. bit.bio aims to leverage technology to increase efficiency of human cell engineering and accelerate the development of highly scalable cell therapies that are capable of treating millions of patients. REDWOOD CITY, Calif. and CAMBRIDGE, UK, Aug. 24, 2023 /PRNewswire/ -- Synthego, a leading provider of industrialized genome editing solutions that accelerate discovery to clinic journey, and bit.bio, the company coding human cells for novel cures, today announced a strategic partnership to build a platform centered on the implementation of synthetic circuitry in cells for therapeutic application.Teaming up with Synthego will boost bit.bio's genetic engineering capabilities.bit.bio is building a pipeline of cell therapies focused on areas of unmet clinical need. The partnership will apply Synthego's expertise in gene editing to bit.bio's opti-oxTM precision cell programming technology, with the aim of discovering and developing advanced genetic engineering solutions for cell therapies.Synthego will rapidly design, build, test and deliver an end-to-end optimized multiplexed genetic editing strategy

Synthego And Bit.Bio Expand Strategic Partnership To Build A Platform For The Development Of Safer And More Efficient Genetic Engineering Of Human Cells For Cell Therapies

Synthego Corporation, a genome engineering company, has officially opened a manufacturing facility in Redwood City’s Friendly Acres neighborhood.

Synthego opens new biotech life science research lab in Redwood City

Patent Trial and Appeal Board Invalidates Agilent U.S. Patents 10,337,001 and 10,900,034REDWOOD CITY, Calif., May 17, 2023 /PRNewswire/ -- Synthego Corp., a leading provider of genome engineering solutions, has announced a victory in its dispute with Agilent Technologies, Inc., regarding two of Agilent's patents which have been invalidated today by a ruling of the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office.The PTAB ruled in favor of Synthego's petitions seeking to invalidate Agilent's US Patents Nos. 10,337,001 (the '001 patent) and 10,900,034 (the '034 patent) in the Inter Partes Review before the PTAB."This decision by the PTAB is a major victory for the entire CRISPR-enabled research and therapeutics field." Tweet thisThe PTAB's decision invalidates all claims of the Agilent patents, which were directed to guide RNAs having at least one 2'-O-methyl modification ('001 patent) and guide RNAs having certain modifications within 5 nucleotides of their 5' and/or 3' end ('034 patent), as well as methods of using such modified guide RNAs for CRISPR gene editing.Synthego is pleased with the PTAB's ruling, which paves the way for continued innovation in the field of CRISPR-enabled research and therapeutics. By delivering cutting-edge genome engineering solutions, Synthego empowers researchers and contributes to the advancement of CRISPR genomic medicines."This decision by the PTAB is a major victory for the entire CRISPR-enabled research and therapeutics field," stated Paul Dabrowski, CEO of Synthego. "The ruling confirms that the invalidated Agilent patents attempted to claim well-known modifications to guide RNAs already taught by prior art

Synthego Announces Invalidation Of Agilent Patents In Crispr Dispute

Facility Sets the Standard for Quality and Efficiency of Clinical Guide RNA Therapeutic and Diagnostic ManufacturingREDWOOD CITY, Calif., May 11, 2023 /PRNewswire/ -- Synthego Corp., a leading provider of genome engineering solutions, announced today the opening of its state-of-the-art GMP synthesis facility. This new 18,000 square-foot facility supports the growing demand for development of high-quality, CRISPR-enabled in vivo and ex vivo therapeutics by pharma and biopharma clients, including via IND and NDA or BLA enabling clinical studies.The new facility follows current Good Manufacturing Practices (cGMP) and features 24/7 operations with advanced equipment and technologies, including multiple multiplexed manufacturing lines, fully automated controls, and an integrated Manufacturing Execution System (MES). This enables the company to produce a range of oligonucleotides, including synthetic single guide RNAs, setting the standard for quality and compliance in manufacturing gene editing components. The facility also includes dedicated process development, analytical testing, and quality control areas, ensuring that all aspects of the manufacturing process are closely controlled."Sets the standard for quality and efficiency of GMP CRISPR reagent manufacturing" Tweet this"This facility will be essential in supporting the burgeoning field of clinical phase, first-in-human, CRISPR-enabled medicines both for more common genetic diseases but also for rare diseases affecting children for whom other treatments do not exist for," said Adrian Thrasher, M.D., Ph.D., a Clinician and Professor of Pediatric Immunology at University College London Great Ormond Street Institute of Child Health, whose laboratory is developing new CRISPR-enabled medicines for children with rare genetic diseases. "As we move into this new generation of cell and gene therapies, it will be crucial that there are strong, reliable manufacturing capabilities that exist for the necessary components of the CRISPR technology - such as the guide RNA - in order to accelerate the path to clinic and treat patients."Don Kohn, M.D., Distinguished Professor and Clinician of Pediatric Hematology and Oncology at UCLA, whose laboratory pioneered revolutionary genetic therapies for immunocompromised children, added, "Synthego pioneered the mass production of guide RNAs for discovery research that has enabled many of the CRISPR-based cell and gene therapy trials happening today. Having been a key leader in providing the technology for researchers and clinicians, it follows that they are now expanding their capacity to support this research as it translates into the clinic."The new facility has been designed to meet the requirements of both domestic and international regulatory authorities including the FDA, EMA, MHRA, and Health Canada."We are pleased to open Synthego's new GMP facility, solidifying our commitment to provide partners with the highest quality CRISPR guides for the clinical development of therapeutics

Synthego Opens State-Of-The-Art Gmp Guide Rna Manufacturing Facility To Enable Crispr Genomic Medicines

Provides synthetic RNA and gene editing tools

Synthego

Provides synthetic RNA and gene editing tools

Synthego

Provides synthetic RNA and gene editing tools

About

Simplify's Take

What believers are saying

What critics are saying

What makes Synthego unique

6 month growth

1 year growth

2 year growth

Benefits

Recently Posted Jobs

Synthego is Hiring for 0 Jobs on Simplify!